CLINICAL TRIALS PROFILE FOR CHLORAMPHENICOL

All Clinical Trials for CHLORAMPHENICOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00277147 ↗	Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	2006-01-09	This study will evaluate a new (conjugate) vaccine for typhoid fever, which remains a serious disease especially difficult to treat in developing countries. Salmonella typhi, the bacteria causing typhoid fever, have become resistant to several antibiotics increasing the difficulty of treating the disease. The disease may have serious complications effecting bones, brain, and intestines, with permanent injury or death. Methods to control typhoid fever, such as a sanitary water and food supply, along with effective sewage treatment, are not likely to be available soon in those countries. NIH scientists developed a vaccine called Vi, made of a polysaccharide (a chain of linked sugars) from the surface of Salmonella typhi, the bacteria that cause typhoid fever. It has been approved by the World Health Organization and is licensed in 94 countries. It is effective in adults but not in young children. Clinical trials have shown that chemically binding the Vi to a protein to form a "conjugate vaccine" has improved and extended its efficacy to children (conjugate vaccines to other bacteria, notably meningitis causing bacteria have been used extensively and successfully). Now NIH scientists have developed another vaccine for typhoid fever - using a polysaccharide from fruit, known as pectin. The pectin has been chemically treated so that it resembles Vi. The treated pectin, O-acetyl pectin, is bound to a protein; exoprotein A, (rEPA). The result is a conjugate, as was formed for Vi. Similarly to the Vi conjugate it induces antibodies against Salmonella typhi in laboratory animals. If the O-acetyl pectin conjugate proves successful, it will be evaluated in children ages 5 to 14 years old and in infants, toward using it with routine vaccines for infants. Volunteers ages 18 to 45 who do not have an allergy to fruit pectin and who have not been vaccinated against nor had typhoid fever within the last 5 years may be eligible for this study. Volunteers will undergo several tests at their first visit to the clinic for this study. A blood sample (about 2/3 of an ounce) will be taken to test for HIV, hepatitis B and C, complete blood count, liver functions, blood chemistry and pregnancy in women of childbearing age. The blood sample will also be tested for antibodies to Vi, rEPA (the protein of the conjugate), and pectin. There will also be a urine collection for testing. If the laboratory tests are acceptable, volunteers will be asked to return to the clinic on a...
NCT00372541 ↗	Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children	Completed	Makerere University	Phase 3	2006-09-01	Acute lower respiratory tract infections are a leading cause of morbidity and mortality in sub Saharan Africa. The World Health Organisation (WHO) still recommends intravenous chloramphenicol for the treatment of severe pneumonia in children aged less than five years. However, up to 20% of children fail treatment due to the emergence of resistance by bacteria. Several centers now use ceftriaxone, a third generation cephalosporin, which is reported to be efficacious in the treatment of severe pneumonia. However the high cost of ceftriaxone is too prohibitive to allow for its routine use in resource constrained countries. The purpose of this study is to compare chloramphenicol and ceftriaxone in the treatment of severe pneumonia in children under five. We hypothesize that 92.7% of children who receive once daily intravenous ceftriaxone (75 mg/kg body weight)for 7 days, will recover from severe pneumonia compared to 80.2 % of those who receive intravenous chloramphenicol (25mg/kg body weight/dose every 6 hours for 7 days).
NCT00579956 ↗	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis	Unknown status	Mahidol University	N/A	2007-12-01	Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.
NCT00579956 ↗	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis	Unknown status	Wellcome Trust	N/A	2007-12-01	Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.
NCT00579956 ↗	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis	Unknown status	University of Oxford	N/A	2007-12-01	Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is a major cause of community-acquired septicaemia in northeast Thailand. Common manifestations include cavitating pneumonia, hepatic and splenic abscesses, and soft tissue and joint infections. Despite improvements in diagnostic procedures and treatment, the mortality of severe melioidosis remains unacceptably high - approximately 35% with currently used antibiotics (ceftazidime or co-amoxiclav). There is clear evidence that antibiotics can affect mortality; the use of ceftazidime rather than previous regimens (doxycycline + chloramphenicol + co-trimoxazole) led to a 50% reduction in mortality from 80% to 35%. However, the mortality in the first 48 hours has not been altered by any treatment regimen. A key question is whether alternative antibiotics could improve early outcome. The hypothesis tested is that meropenem is superior to ceftazidime in terms of mortality for the treatment of melioidosis.
NCT00619203 ↗	Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis	Completed	University of Malawi College of Medicine	Phase 3	2008-03-01	Bacterial meningitis remains a significant cause of morbidity and mortality in children, especially in countries with limited resources. Efforts to improve the grim outcome have included altering the first line antibiotic therapy, controlling seizures and managing fluids more carefully. Adjuvant therapy of steroids has been used with limited success in children in the West and with no proven value in Malawi and other resource constrained settings. Glycerol has been used to reduce brain oedema in neurosurgery and it has recently been shown to reduce morbidity in childhood meningitis in South America. Paracetamol in a high dosage has been shown to reduce inflammation and cytokine levels in septicaemia with improved outcomes in adults. In Malawi the investigators have tried adjuvant steroids with no improvement in outcome of childhood meningitis. They have recently concluded a study of ceftriaxone which has shown no improvement in mortality though there is less hearing loss than with chloramphenicol and benzyl penicillin. Following the encouraging results of the Childhood South American Study it is important to assess the use of adjuvant glycerol in children in the investigators' setting. Paracetamol is routinely used in meningitis because of the accompanying fever and headache. This is an opportunity to study its place as adjuvant therapy more carefully than has previously been done. The investigators propose a prospective, randomized, double blind 2 by 2 factorial designed study to assess the advantage of ceftriaxone (antibiotic) given with paracetamol and glycerol in combination, singly or with neither adjuvant therapy in childhood bacterial meningitis.
NCT00732966 ↗	Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?	Unknown status	Assaf-Harofeh Medical Center	N/A	2008-09-01	Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to evaluate whether CYP2C9 polymorphism has a significant clinical influence on the blood pressure lowering effect of losartan and valsartan. Weather there is a genetic importance in choosing the right ARB for the right patient.

Clinical Trial Conditions for CHLORAMPHENICOL

Condition Name

Condition Name for CHLORAMPHENICOL
Intervention	Trials
Dry Eye	1
Scrub Typhus	1
Glaucoma	1
Severe Pneumonia	1

Condition MeSH

Condition MeSH for CHLORAMPHENICOL
Intervention	Trials
Pneumonia	2
Meningitis	1
Pterygium	1
Dental Pulp Necrosis	1

Clinical Trial Locations for CHLORAMPHENICOL

Trials by Country

Trials by Country for CHLORAMPHENICOL
Location	Trials
Thailand	5
Uganda	3
Brazil	3
Iran, Islamic Republic of	3
Bangladesh	1

Trials by US State

Trials by US State for CHLORAMPHENICOL
Location	Trials
Maryland	1

Clinical Trial Progress for CHLORAMPHENICOL

Clinical Trial Phase

Clinical Trial Phase for CHLORAMPHENICOL
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CHLORAMPHENICOL
Clinical Trial Phase	Trials
Unknown status	8
Completed	7
Active, not recruiting	1

Clinical Trial Sponsors for CHLORAMPHENICOL

Sponsor Name

Sponsor Name for CHLORAMPHENICOL
Sponsor	Trials
Shahid Beheshti University of Medical Sciences	3
University of Oxford	2
Mahidol Oxford Tropical Medicine Research Unit	1

Sponsor Type

Sponsor Type for CHLORAMPHENICOL
Sponsor	Trials
Other	30
NIH	1
U.S. Fed	1

CHLORAMPHENICOL Market Analysis and Financial Projection

Last updated: April 26, 2026

Clinical Trials Update, Market Analysis, and Projection for Chloramphenicol

Chloramphenicol is an older, off-patent antibiotic whose current commercial footprint is dominated by generic products, limited licensed use tied to resistance patterns and safety restrictions, and occasional niche hospital procurement rather than sustained global growth. Market outcomes are driven by (1) regulatory constraints around marrow toxicity, (2) clinician and guideline behavior after widespread use of safer alternatives, and (3) stable demand in specific infectious disease settings. No active, sponsor-led late-stage development program is evident for chloramphenicol as a brand-new systemic therapy; most clinical activity is localized, method-focused, or compares formulations rather than advancing a new chemical entity.

---

What is chloramphenicol’s current clinical development status?

Late-stage (Phase 3/Registration) evidence

No current, clearly identifiable Phase 3 or registration-defining program for chloramphenicol is visible in public trial registries in a way that supports a credible “late-stage pipeline” update. The drug is widely treated as therapeutically established and commercially generic, so the dominant clinical footprint is not brand-sponsored registration trials but comparative studies, formulation work, and guideline-driven use.

Earlier-phase and study types that still appear

For older antibiotics like chloramphenicol, residual clinical activity typically clusters into four buckets:

• Formulation or bioavailability work (especially for ophthalmic or topical uses)
• Comparative efficacy or susceptibility research (often observational)
• Stewardship and resistance surveillance (hospital- or region-level)
• Mechanistic or safety monitoring studies in constrained indications

This pattern matters for market projection: it implies minimal contribution from “new product lifecycle expansion.” Growth is more likely to come from stable procurement in defined indications and any incremental uptake from localized resistance trends, not from a new blockbuster launch.

Regulatory-driven clinical constraints shaping real-world use

Key clinical behavior is shaped by the known risk profile:

• Aplastic anemia and bone marrow suppression risk
• Gray baby syndrome in neonates with systemic exposure
• Risk-based restrictions that limit use to specific contexts or require monitoring, particularly outside tightly controlled settings

These constraints reduce market elasticity: even when susceptibility patterns improve, prescribers and regulators rarely swing to broad, high-volume systemic use.

---

How big is the chloramphenicol market today?

Market structure

Chloramphenicol’s market is structurally generic:

• Multiple manufacturers across regions
• Lower pricing power and limited premium pricing potential
• Procurement-driven demand tied to hospital formularies and national essential medicines lists

Where demand concentrates

Demand tends to concentrate in uses with established protocols and controlled supply chains, commonly including:

• Ophthalmic indications (topical drops/ointments)
• Topical use in select skin infections or ocular surface infections where appropriate susceptibility and local guidance align
• Hospital inventory use where alternatives face resistance or availability constraints

Systemic use is generally more restricted due to safety concerns and the availability of safer, more preferred alternatives.

Implication for analytics

Because the market is generic and demand is procurement-based, “market growth” typically tracks:

• demographic and infection incidence patterns at a stable level,
• resistance-driven shifts at the margin,
• and regulatory or stewardship actions that constrain systemic prescribing.

In such a model, forecasts are rarely steep.

---

What drives demand and how do safety rules affect it?

Demand drivers

1. Antibiotic susceptibility landscape
   • Where chloramphenicol remains active against certain gram-negative or ocular pathogens, clinicians can maintain use in defined settings.
2. Formulary inertia
   • Hospitals tend to keep stable, tested antibiotics in core formularies when resistance and safety monitoring remain manageable.
3. Local guideline alignment
   • Some health systems retain chloramphenicol in limited indications due to cost-effectiveness versus newer agents.

Safety and regulatory dampeners

1. Marrow toxicity risk
   • Limits systemic adoption and pushes use toward topical/controlled indications.
2. Neonatal systemic risk
   • Restricts broader pediatric systemic use and reduces volume potential.
3. Stewardship pressures
   • Modern prescribing norms prefer safer, more targeted agents, keeping chloramphenicol as a back-up rather than a first-line option.

---

What is the forecast outlook for chloramphenicol (volume and revenue)?

Revenue growth: low single digits, with regional volatility

A realistic projection for an off-patent, safety-restricted antibiotic is:

• Nominal revenue growth: low single digits globally, with periodic dips from tender cycles and substitution by preferred alternatives.
• Upside scenarios: localized demand rebound when resistance patterns favor chloramphenicol or when supply conditions constrain alternatives.
• Downside scenarios: tighter stewardship, tighter regulatory enforcement, or substitution toward newer agents.

Volume trajectory

• Global volume: likely flat to modestly rising, because base-case prescribing remains constrained but demand persists in defined uses.
• Topical/ophthalmic: more resilient than systemic due to risk profile.
• Systemic: structurally capped by safety constraints.

Scenario table (directional, not a steep cycle)

Driver	Base case	Upside case	Downside case
Stewardship restrictions	Tight, stable	Slight relaxation in niche settings	Further tightening; systemic use shrinks
Resistance patterns	Neutral to mildly favorable	Regional resistance makes chloramphenicol relevant	Widespread resistance reduces use
Supply and pricing	Competitive generics; price erosion	Stable tenders; fewer pricing shocks	Price compression and substitutions
Regulatory risk management	Monitoring remains required	Improved guidance supports controlled use	Stronger restrictions reduce availability

---

Where can a new entrant or investor find “signal” despite off-patent status?

High-value opportunities exist only in execution, not in IP

With chloramphenicol’s chemistry long off-patent, the only route to meaningful incremental returns is:

• Formulation differentiation (stability, drop uniformity, ocular tolerability)
• Supply-chain reliability (tender wins and consistent inventory)
• Regulatory strategy for specific local filings
• Fixed-dose or combination products only where allowed and where clinical evidence supports added value

Clinical development strategy implied by the landscape

Any future clinical plan is likely to be:

• small-scale,
• formulation/quality-focused,
• and tied to specific regulatory pathways rather than full systemic Phase 3 efficacy packages.

This keeps capital needs comparatively contained, but also limits upside to market share rather than new category creation.

---

Competitive landscape: what substitutes chloramphenicol?

Substitution pressure generally comes from:

• Fluoroquinolones (where appropriate)
• Aminoglycosides and other ophthalmic alternatives
• Macrolides and cephalosporins depending on indication and susceptibility
• Modern broad-spectrum agents when stewardship allows

The competitive reality is not “chloramphenicol versus the best drug,” but “chloramphenicol versus the safest and most protocol-compliant option.” Chloramphenicol competes primarily where cost, historical guideline inclusion, or susceptibility patterns sustain it.

---

Key Takeaways

• Chloramphenicol is an established, off-patent antibiotic whose clinical and commercial trajectory is shaped more by safety restrictions and prescribing norms than by new pipeline breakthroughs.
• Publicly visible late-stage, registration-style development activity is not apparent in a way that supports a major pipeline-driven growth thesis.
• Market demand is procurement-driven and niche, concentrated in topical/ophthalmic or tightly controlled settings, with systemic use structurally capped by marrow toxicity concerns.
• Forecasts for chloramphenicol revenue are best modeled as flat to low single-digit growth with regional tender and stewardship volatility, not as a high-growth category.

---

FAQs

1) Is chloramphenicol still used clinically today?

Yes, but usage is constrained. It remains present mainly where topical/controlled indications align with susceptibility patterns and where safety monitoring is manageable.

2) Does chloramphenicol have meaningful patent protection that can support premium pricing?

No. The product is generally treated as off-patent and commercialized via generics, limiting premium pricing and category growth driven by IP.

3) What is the biggest factor limiting systemic adoption?

The risk of bone marrow suppression and related hematologic toxicity, including heightened neonatal concerns, drives regulatory and prescribing restrictions.

4) What types of clinical studies still matter for chloramphenicol?

Formulation quality work, bioavailability/stability improvements, and localized comparative or surveillance studies that influence formulary decisions.

5) How should investors think about upside?

Upside is most likely to come from share gains via differentiated formulations, reliable tender execution, and regulatory fit in specific jurisdictions, not from a new high-volume systemic launch.

---

References (APA)

[1] ClinicalTrials.gov. (n.d.). Chloramphenicol studies. https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). (n.d.). Public assessment documents and product information for chloramphenicol (where applicable). https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration (FDA). (n.d.). Drug safety communications and labeling information related to chloramphenicol. https://www.fda.gov/
[4] WHO. (n.d.). Essential medicines lists (chloramphenicol-related entries where applicable). https://www.who.int/